BIIB
Proxy Governance Endorses All Four Biogen Idec Director Nominees
Wednesday, June 11, 2008 BiopharmaWatch Research 1 min read Key Takeaway: Proxy Governance Endorses All Four Biogen Idec Director Nominees
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis
Full Press Release Details
Proxy Governance Endorses All Four Biogen Idec Director Nominees.